Alzheimer Forschung Initiative e.V. Nicht-medikamentöse Behandlung. https://www.alzheimer-forschung.de/alzheimer/behandlung/nicht-medikamentoese-behandlung/ (Zugriff: Dezember 2018)

Astarita G et al: Deficient liver biosynthesis of docosahexaenoic Acid correlates with cognitive impairment in Alzheimer’s disease. PLoS One 2010; 5, e12538.

Brinks R, Landwehr S, Waldeyer R. Age of onset in chronic diseases: New method and application to dementia
in Germany. Popul Health Metr. 2013 May 2;11:6. doi: 10.1186/1478-7954-11-6.

Bundesministerium für Bildung und Forschung – 3 Millionen Deutsche könnten im Jahr 2050 an Demenz leiden,
https://www.bmbf.de/de/3-millionen-deutsche-koennten-im-jahr-2050-an-demenz-leiden-4826.html, Zugriff:
November 2018

Cansev M et al: Giving uridine and/or docosahexaenoic acid orally to rat dams during gestation and nursing increases synaptic elements in brains of weanling pups. Dev Neurosci. 2009; 31: 181-92.

Conquer JA et al: Fatty acid analysis of blood plasma of patients with Alzheimer’s disease, other types of dementia, and cognitive impairment. Lipids. 2000; 35: 1305-12.

Corrigan FM et al: Tin and fatty acids in dementia. Prostaglandins Leukot Essent Fatty Acids. 1991; 43: 229-38. PubMed PMID: 1946550.

Corrigan FM et al: Abnormal content of n-6 and n-3 long-chain unsaturated fatty acids in the phosphoglycerides and cholesterol esters of parahippocampal cortex from Alzheimer’s disease patients and its relationship to acetyl CoA content. Int J Biochem Cell Biol 1998; 30, 197-207. PubMed PMID: 9608673.

Deuschl G, Maier W et al. S3-Leitlinie Demenzen 2016. In: Deutsche Gesellschaft für Neurologie, Hrsg. Leitlinien für Diagnostik und Therapie in der Neurologie.

Deutsche Alzheimer Gesellschaft e.V. – Informationsblatt 1: Die Häufigkeit von Demenzerkrankungen,
http://www.deutschealzheimer.de/fileadmin/alz/pdf/factsheets/infoblatt1_haeufigkeit_demenzerkrankungen_dalzg.pdf, Zugriff: November 2018

Efficacy of Souvenaid in Mild Alzheimer’s Disease: Results from a Randomized, Controlled Trial. Journal of
Alzheimer’s Disease 31 (2012) 225–236.

Feart C, Samieri C, Rondeau V, et al.: Adherence to a Mediterranean diet, cognitive decline, and risk of
dementia. JAMA 2009; 302: 638-648.

Glasø M et al: Reduced concentrations of several vitamins in normal weight patients with late-onset dementia of the Alzheimer type without vascular disease. J Nutr Health Aging. 2004; 8: 407-13.

Gold CA, Budson AE: Memory Loss in Alzheimer’s Disease: Implications for Development of Therapeutics. Expert Rev Neurother. 2008; 8: 1879-1891.

Gu Y et al: Food Combination and Alzheimer Disease Risk: A Protective Diet. Arch Neurol, 2010. 2084.

Igarashi M et al: Disturbed Choline Plasmalogen and Phospholipid Fatty Acid Concentrations in Alzheimer’s Disease Prefrontal Cortex. JAD 2011; 24, 507-517.

Kamphuis PJ, Scheltens P: Can nutrients prevent or delay onset of Alzheimer’s disease? J Alzheimers Dis. 2010; 20(3):765-75.

Köseoglu E, Karaman Y: Relations between homocysteine, folate and vitamin B12 in vascular dementia and in Alzheimer disease. Clin Biochem. 2007; 40: 859-63.

Livingston G et al. Dementia prevention, intervention, and care. Lancet 2017 Dec 16;390(10113):2673-2734.

Lopes da Silva S, Europ J Neurol 2012;19 (Suppl. 1):458-807.

Lopes da Silva S et al. Plasma nutrient status of patients with Alzheimer’s disease: Systematic review and
meta-analysis. Alzheimers Dement 2013 Oct 18. pii: S1552-5260(13)02464-3.

Mulder C et al, J Neural Transm 2003; 110: 949-955.

Pettegrew JW et al: Brain membrane phospholipid alterations in Alzheimer’s disease. Neurochem Res 2001 26, 771-782.

Polidori MC et al: Plasma antioxidant status, immunoglobulin g oxidation and lipid peroxidation in demented patients: relevance to Alzheimer disease and vascular dementia. Dement Geriatr Cogn Disord. 2004; 18: 265-70.

Pooler AM et al: Uridine enhances neurite outgrowth in nerve growth factor-differentiated PC12 [corrected]. Neuroscience. 2005; 134(1): 207-14.

Rapoport SI et al: Quantitative contributions of diet and liver synthesis to docosahexaenoic acid homeostasis. Prostaglandins Leukot Essent Fatty Acids 2010; 82, 273-27620.R Sakamoto T et al: Oral supplementation with docosahexaenoic acid and uridine-5′-monophosphate increases dendritic spine density in adult gerbil hippocampus. Brain Res. 2007; 1182: 50-9.

Ravaglia G et al: Plasma amino acid concentrations in patients with amnestic mild cognitive impairment or Alzheimer disease. Am J Clin Nutr. 2004; 80: 483-8.

Robert Koch-Institut (Hrsg) – Beiträge zur Gesundheitsberichterstattung des Bundes 2005,
https://www.rki.de/DE/Content/Gesundheitsmonitoring/Gesundheitsberichterstattung/GBEDownloadsB/Armut.pdf
%3F__blob%3DpublicationFile. Zugriff: November 2018

Scarmeas N et al: Mediterranean diet, Alzheimer disease, and vascular mediation. Arch Neurol 2006; 63: 1709-1717.

Scheff SW et al: Hippocampal synaptic loss in early Alzheimer’s disease and mild cognitive impairment. Neurobiol Aging. 2006; 27: 1372-84.

Scheff SW et al, Neurology 2007;68: 1501-8.

Scheltens P et al: Efficacy of a medical food in mild Alzheimer’s Disease: a randomized controlled trial. Alzheimer’s & Dementia. 2010; 6: 1-10.

Scheltens P et al: Efficacy of Souvenaid in mild Alzheimer’s disease – results from a randomised, controlled trial. J Alzheimer’s Dis. 2012;31:225-36.

Shah R et al: Souvenaid® as an add-on intervention in patients with mild to moderate Alzheimer’s disease using Alzheimer’s disease medication: results from a randomized, controlled, double-blind study (S-Connect). CTAD, San Diego, November 2011; J Nutr Health Aging (Nov suppl.).

Schelten P et al. Efficacy of a medical food in mild Alzheimer‘s disease: A randomized, controlled trial.
Alzheimer’s & Dementia 6 (2010) 1-10.

Sijben JW, Europ J: Neurol 2012; 19 (Suppl. 1): 458-807.

Smollich M (2015) Omega-3 fatty acids and brain function. Ernahrungs Umschau 62(10):170–177.

Soininen H et al. 24-month intervention with a specific multinutrient in people with prodromal Alzheimer’s
disease (LipiDiDiet): a randomised, double-blind, controlled trial. Lancet Neurol 2017; 16: 965–75.

Sperling RA et al: Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011; 7: 280–92.

Terry RD et al: Physical basis of cognitive alterations in Alzheimer’s disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991; 30: 572-80.

Terry RD: Alzheimer’s disease and the aging brain. J Geriatr Psychiatry Neurol 2006; 19: 125-8.

Wang L et al: Dietary uridine-5′-monophosphate supplementation increases potassium-evoked dopamine release and promotes neurite outgrowth in aged rats. J Mol Neurosci. 2005; 27: 137-45.

Wurtman RJ et al: Synaptic proteins and phospholipids are increased in gerbil brain by administering uridine plus docosahexaenoic acid orally. Brain Res. 2006; 1088: 83-92.

Wurtman RJM et al: Annu Rev Nutr 2009; 29: 59-87.